FDA Approves First Non-Antipsychotic Treatment

What Did the FDA Approve and Why Does It Matter?

The U.S. Food and Drug Administration has expanded the indication for Auvelity, originally approved for major depressive disorder, to include treatment of agitation associated with dementia. The medication combines dextromethorphan hydrobromide, which acts on NMDA receptors and sigma-1 receptors in the brain, with bupropion hydrochloride, which extends the half-life and bioavailability of dextromethorphan by inhibiting its metabolism.

Agitation is among the most distressing neuropsychiatric symptoms experienced by people living with dementia, frequently driving caregiver burnout and earlier transitions to institutional care. Until recent years, clinicians often relied on off-label antipsychotic prescriptions, despite long-standing FDA black box warnings highlighting increased mortality risk in elderly patients with dementia-related psychosis. A non-antipsychotic option backed by regulatory approval represents a meaningful shift in the therapeutic landscape for these vulnerable patients and their families.

How Does the Drug Work in the Brain?

Dextromethorphan, long familiar as a cough suppressant, has more complex central nervous system effects at therapeutic doses used for psychiatric indications. It functions as an uncompetitive NMDA receptor antagonist and a sigma-1 receptor agonist, while also influencing serotonin and norepinephrine reuptake. These combined actions are thought to dampen hyperexcitable neural circuits implicated in mood and behavioral dysregulation.

Bupropion, a norepinephrine-dopamine reuptake inhibitor commonly prescribed for depression and smoking cessation, plays a critical pharmacokinetic role in the combination. By inhibiting the cytochrome P450 2D6 enzyme that metabolizes dextromethorphan, bupropion allows therapeutic concentrations of dextromethorphan to be sustained at lower oral doses. The fixed combination was designed specifically to leverage this interaction in a controlled, predictable way.

What Should Patients and Caregivers Know About Safety?

Antipsychotic medications used off-label for dementia-related behaviors carry well-documented risks including sedation, falls, stroke, and increased all-cause mortality, as reflected in the FDA's class-wide boxed warning for this population. The availability of a regulator-approved, non-antipsychotic alternative may reduce reliance on these higher-risk agents and align prescribing with safer pharmacological practice.

However, clinicians and caregivers should remain attentive to potential side effects associated with the components of Auvelity, including dizziness, headache, gastrointestinal symptoms, and the seizure-threshold-lowering properties of bupropion. Drug interactions, particularly with other serotonergic medications, are an important consideration. Non-pharmacological strategies — addressing pain, infection, environmental triggers, and unmet needs — remain a cornerstone of care and should be optimized alongside any medication.